Skip to main content
NVDA+0.88%AAPL+0.82%MSFT+0.11%GOOGL+1.59%AMZN+1.77%TSM+2.90%SPCX+2.62%AVGO+4.04%META-0.92%TSLA+3.57%LLY+0.02%BRK-B-0.65%MU+2.94%SKHY+2.61%WMT-0.96%AMD+5.23%JPM+0.64%V-0.80%XOM-1.90%JNJ+0.38%ASMLa+2.84%MA-0.47%ABBV+0.09%INTC+3.75%1398.HK+2.15%CVX-1.73%0700.HK-0.31%COST-1.27%CSCO+1.86%KO-0.74%ORCL+4.56%UNH-0.27%PG-0.74%BAC+0.35%1816.HK+1.32%3988.HK+0.66%CAT+2.69%DELL+8.20%HD-0.26%PM+0.74%0857.HK-0.98%0939.HK+0.81%AMAT+2.36%AP2d+2.44%GE+3.22%1288.HK+0.60%LRCX+1.40%0005.HK-5.56%NVS+1.15%MS+1.99%USDJPY+0.65%NZDMXN+0.63%AUDJPY+0.60%EURUSD-0.53%GBPUSD-0.51%USDMXN+0.50%EURSEK-0.49%EURZAR-0.49%GBPZAR-0.48%AUDDKK+0.48%EURAUD-0.47%NZDJPY+0.46%GBPAUD-0.44%USDCHF+0.44%GBPTRY+0.41%AUDCHF+0.39%CADJPY+0.37%EURNZD-0.35%EURCNH-0.34%CHFSEK-0.33%GBPHKD+0.32%GBPNZD-0.30%USDCAD+0.30%EURHKD-0.29%GBPMXN-0.28%USDDKK+0.28%EURSGD-0.27%GBPSGD-0.27%AUDNOK+0.25%NZDCHF+0.24%SGDJPY+0.24%AUDCAD+0.23%CHFJPY+0.23%EURNOK-0.23%GBPCAD-0.22%EURCAD-0.22%USDSEK-0.22%USDZAR-0.21%AUDSGD+0.20%NZDUSD-0.20%NOKJPY+0.20%USDTRY+0.18%USDILS+0.16%EURPLN-0.15%CADCHF+0.14%NZDSGD+0.14%GBPJPY+0.14%EURJPY+0.13%USDPLN+0.13%AUDNZD+0.13%PLNJPY+0.12%EURCHF-0.11%CHFSGD-0.10%NZDCAD+0.10%EURCZK-0.09%GBPCHF-0.08%AUDUSD-0.06%CHFNOK-0.05%USDNOK+0.05%USDCNH-0.05%USDCOP-0.04%USDHKD+0.04%EURGBP-0.02%USDSGD0.00%EURDKK0.00%USDTHB0.00%COCOA+1.68%HG1+1.64%COFFEE-1.47%USOIL-1.17%GAUUSD+1.02%XAUUSD+1.02%COTTON-0.95%XAGUSD+0.82%GAGUSD+0.82%UKOIL-0.76%S1-0.69%C1-0.63%BTCUSD+0.74%ETHUSD+23.96%USDTUSD+0.04%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT-0.30%ZECUSDT+6.74%DOGEUSD+20.65%XMRUSDT-0.72%LINKUSD+25.58%BCHUSDT+3.51%XLMUSD+0.28%UNIUSD+0.64%LTCUSD+17.89%SUIUSD+1.18%HBARUSDT-1.04%TONUSD+41.71%TAOUSDT+0.77%AAVEUSD-1.76%DOTUSDT-1.29%ICPUSDT-1.37%ONDOUSDT+0.80%WLDUSDT+1.06%ARBUSDT+0.37%JUPUSDT+1.02%INJUSDT+1.81%ATOMUSDT-0.76%STXUSDT-0.75%TIAUSDT-1.98%FETUSDT+3.93%PYTHUSDT-3.55%SEIUSDT+0.54%IMXUSDT+0.43%GRTUSDT+2.01%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+1.06%POLUSDT+0.29%AXSUSDT+0.72%EOSUSDT+0.98%FARTCOINUSDT+2.47%DYDXUSDT+2.14%GALAUSDT+0.41%ORDIUSDT+2.05%RONINUSDT+1.89%NOTUSDT+1.92%NVDA+0.88%AAPL+0.82%MSFT+0.11%GOOGL+1.59%AMZN+1.77%TSM+2.90%SPCX+2.62%AVGO+4.04%META-0.92%TSLA+3.57%LLY+0.02%BRK-B-0.65%MU+2.94%SKHY+2.61%WMT-0.96%AMD+5.23%JPM+0.64%V-0.80%XOM-1.90%JNJ+0.38%ASMLa+2.84%MA-0.47%ABBV+0.09%INTC+3.75%1398.HK+2.15%CVX-1.73%0700.HK-0.31%COST-1.27%CSCO+1.86%KO-0.74%ORCL+4.56%UNH-0.27%PG-0.74%BAC+0.35%1816.HK+1.32%3988.HK+0.66%CAT+2.69%DELL+8.20%HD-0.26%PM+0.74%0857.HK-0.98%0939.HK+0.81%AMAT+2.36%AP2d+2.44%GE+3.22%1288.HK+0.60%LRCX+1.40%0005.HK-5.56%NVS+1.15%MS+1.99%USDJPY+0.65%NZDMXN+0.63%AUDJPY+0.60%EURUSD-0.53%GBPUSD-0.51%USDMXN+0.50%EURSEK-0.49%EURZAR-0.49%GBPZAR-0.48%AUDDKK+0.48%EURAUD-0.47%NZDJPY+0.46%GBPAUD-0.44%USDCHF+0.44%GBPTRY+0.41%AUDCHF+0.39%CADJPY+0.37%EURNZD-0.35%EURCNH-0.34%CHFSEK-0.33%GBPHKD+0.32%GBPNZD-0.30%USDCAD+0.30%EURHKD-0.29%GBPMXN-0.28%USDDKK+0.28%EURSGD-0.27%GBPSGD-0.27%AUDNOK+0.25%NZDCHF+0.24%SGDJPY+0.24%AUDCAD+0.23%CHFJPY+0.23%EURNOK-0.23%GBPCAD-0.22%EURCAD-0.22%USDSEK-0.22%USDZAR-0.21%AUDSGD+0.20%NZDUSD-0.20%NOKJPY+0.20%USDTRY+0.18%USDILS+0.16%EURPLN-0.15%CADCHF+0.14%NZDSGD+0.14%GBPJPY+0.14%EURJPY+0.13%USDPLN+0.13%AUDNZD+0.13%PLNJPY+0.12%EURCHF-0.11%CHFSGD-0.10%NZDCAD+0.10%EURCZK-0.09%GBPCHF-0.08%AUDUSD-0.06%CHFNOK-0.05%USDNOK+0.05%USDCNH-0.05%USDCOP-0.04%USDHKD+0.04%EURGBP-0.02%USDSGD0.00%EURDKK0.00%USDTHB0.00%COCOA+1.68%HG1+1.64%COFFEE-1.47%USOIL-1.17%GAUUSD+1.02%XAUUSD+1.02%COTTON-0.95%XAGUSD+0.82%GAGUSD+0.82%UKOIL-0.76%S1-0.69%C1-0.63%BTCUSD+0.74%ETHUSD+23.96%USDTUSD+0.04%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT-0.30%ZECUSDT+6.74%DOGEUSD+20.65%XMRUSDT-0.72%LINKUSD+25.58%BCHUSDT+3.51%XLMUSD+0.28%UNIUSD+0.64%LTCUSD+17.89%SUIUSD+1.18%HBARUSDT-1.04%TONUSD+41.71%TAOUSDT+0.77%AAVEUSD-1.76%DOTUSDT-1.29%ICPUSDT-1.37%ONDOUSDT+0.80%WLDUSDT+1.06%ARBUSDT+0.37%JUPUSDT+1.02%INJUSDT+1.81%ATOMUSDT-0.76%STXUSDT-0.75%TIAUSDT-1.98%FETUSDT+3.93%PYTHUSDT-3.55%SEIUSDT+0.54%IMXUSDT+0.43%GRTUSDT+2.01%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+1.06%POLUSDT+0.29%AXSUSDT+0.72%EOSUSDT+0.98%FARTCOINUSDT+2.47%DYDXUSDT+2.14%GALAUSDT+0.41%ORDIUSDT+2.05%RONINUSDT+1.89%NOTUSDT+1.92%
TM

Treace Medical Concepts, Inc. (TMCI)

NASDAQ • Healthcare

$4.42
+$0.15 (+3.5%)
Market open

Last close at October 26, 2026 at 20:00 UTC

Open$4.27
Previous Close$4.42
Day Range$4.25 - $4.43
Avg. Volume (3M)205.2K
Market Cap$290M
52 Week Range
$1.17$6.91
Next EarningsIn 10 daysNov 6, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$45.3M100%
Gross Profitminus cost of goods$35.6M78%

In plain terms: out of every $100 in revenue, Treace Medical Concepts, Inc. currently loses $35.

Fundamentals & Financials

Revenue (TTM)
$205.3M
Net Income (TTM)
-$59.5M
EPS (TTM)
-$0.93
ROA (TTM)
-32.87%
Current Ratio
2.9

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+21.0%Q1 2026-$0.12
+9.7%Q2 2026-$0.28
+19.5%Q3 2026-$0.24
Next

Nov 6

in 10 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +19.5%

Treace Medical Concepts topped expectations on both the top and bottom line in the second fiscal quarter of 2026 (period ended June 30, 2026; reported August 7, 2026), even as revenue fell 4% year over year to roughly $45 million from about $47 million a year ago, reflecting results in its bunion and related deformity correction portfolio led by the Lapiplasty System. EPS came in at -$0.24, which topped the -$0.30 estimate by $0.06 and improved from -$0.28 a year ago (~14% better). On sales, revenue of $45.4 million topped the $44.0 million estimate, +3%. Profitability held at a high gross margin of around 79%, but operating income remained negative at roughly -$15 million, with operating margin at -33%, and net income was about -$15.9 million, up ~9% from a net loss of about -$17 million a year ago. Cash generation was also negative, with negative operating cash flow of roughly -$4.7 million. For the next period, consensus calls for EPS of -$0.26 on revenue of $47.7 million.

Next report — what to expect

Treace Medical Concepts, Inc. (TMCI) reports on November 5, 2026. Wall Street expects EPS of -$0.26 on revenue of $47.7 million. For trailing context, revenue declined -4.2% year over year last quarter. TMCI has beaten EPS in 8 of its 8 most recent quarters.

View full earnings history

About Treace Medical Concepts, Inc.

Treace Medical Concepts, Inc. designs, manufactures, and markets medical devices for foot and ankle surgery in the United States. Listed on NASDAQ as TMCI, the company focuses on bunion and related deformity correction, with FY2025 revenue of $212.7 million in the healthcare equipment field.

Name
Treace Medical Concepts, Inc.
CEO
John T. Treace
Website
www.treace.com
Industry
Healthcare
Year Founded
2013
Employees
450

Today's Snapshot

AI-generated

So far today, TMCI is trading slightly higher at 4.43, in line with a flat sector. TMCI reports earnings on 6 November.

Trading Volume

Below 10d avg (180.9K)

48.7K

vs S&P 500 Today

Moderate Underperformance

-0.32%

Updated: October 27, 2026 at 16:41 UTC

Technical Indicators

5 Buy2 Neutral1 Sell
TMCI shows a mix of short-term strength and overbought signals while lacking clear trend conviction. Price sits above its short- and medium-term moving averages and well above the 200-day average, indicating underlying upward bias, yet the ADX is low, signaling a weak trend. Momentum indicators are split: RSI is mildly bullish while Stochastic and Williams%R point to near-term exhaustion, and MACD is essentially neutral. Volatility is moderate and the pivot sits close to the current price, offering a nearby reference. Technical takeaway: Neutral — short-term strength is counterbalanced by overbought oscillators and a lack of trend conviction.
All signals
  • EMA (5 indicators)$3.54 - $4.28
    Buy
  • RSI (14)57.77
    Neutral
  • Stochastic %K (14, 3, 3)86.98
    Sell
  • MACD Level (12, 26)-0.03
    Neutral

Peers & Related Assets

CBLLCeriBell, Inc.
$27.03-0.4%
BVSBioventus Inc.
$14.72-1.6%
KIDSOrthoPediatrics Corp.
$24.02-2.0%
EOLSEvolus, Inc.
$7.17+2.3%
LABStandard BioTools Inc.
$0.6-0.9%
RXSTRxSight, Inc.
$4.93-1.8%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.